December 4, 2020 10:18 AM EST
FDA+

J&J guns for quick drug OK in lung can­cer niche, tak­ing the first step chal­leng­ing As­traZeneca in EGFR

Amber Tong

J&J has leapt straight from a Phase I tri­al to a BLA for ami­van­tam­ab, a bis­pe­cif­ic an­ti­body de­signed to treat a sub­set of metasta­t­ic non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Up­dat­ed: CDER Di­rec­tor Pa­trizia Cavaz­zoni to step down ahead of Trump pres­i­den­cy

Bio­gen of­fers to buy out strug­gling neu­ro part­ner Sage Ther­a­peu­tics

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

A service from the Financial Times